Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Streptococcus pneumoniae as a Cause of Mycotic and Infected Aneurysms in Patients without Respiratory Features: Challenging Diagnoses Aided by 16S PCR.

Seet C, Szyszko T, Perera R, Donati T, Modarai B, Patel S, Tyrrell M, Sallam M, Bell R, Price N, Lyons O.

Ann Vasc Surg. 2019 Oct;60:475.e11-475.e17. doi: 10.1016/j.avsg.2019.02.041. Epub 2019 May 8.

PMID:
31075452
2.

Improving liver lesion characterisation using retrospective fusion of FDG PET/CT and MRI.

Parsai A, Miquel ME, Jan H, Kastler A, Szyszko T, Zerizer I.

Clin Imaging. 2019 May - Jun;55:23-28. doi: 10.1016/j.clinimag.2019.01.018. Epub 2019 Jan 23.

PMID:
30710749
3.

Palatine tonsil SUVmax on FDG PET-CT as a discriminator between benign and malignant tonsils in patients with and without head and neck squamous cell carcinoma of unknown primary.

Pencharz D, Dunn J, Connor S, Siddiqui A, Sriskandan N, Thavaraj S, Jeannon JP, Oakley R, Lei M, Guerrero-Urbano T, Cook GJ, Szyszko TA.

Clin Radiol. 2019 Feb;74(2):165.e17-165.e23. doi: 10.1016/j.crad.2018.10.007. Epub 2018 Nov 16.

PMID:
30454841
4.

Staging Uveal Melanoma with Whole-Body Positron-Emission Tomography/Computed Tomography and Abdominal Ultrasound: Low Incidence of Metastatic Disease, High Incidence of Second Primary Cancers.

Cohen VML, Pavlidou E, DaCosta J, Arora AK, Szyszko T, Sagoo MS, Szlosarek P.

Middle East Afr J Ophthalmol. 2018 Apr-Jun;25(2):91-95. doi: 10.4103/meajo.MEAJO_96_18.

5.

Optimizing arginine deprivation for hard-to-treat cancers.

Khadeir R, Szyszko T, Szlosarek PW.

Oncotarget. 2017 Oct 27;8(57):96468-96469. doi: 10.18632/oncotarget.22099. eCollection 2017 Nov 14. No abstract available.

6.

PET/CT and PET/MRI in head and neck malignancy.

Szyszko TA, Cook GJR.

Clin Radiol. 2018 Jan;73(1):60-69. doi: 10.1016/j.crad.2017.09.001. Epub 2017 Oct 10. Review.

PMID:
29029767
7.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW.

J Clin Oncol. 2017 Jun 1;35(16):1778-1785. doi: 10.1200/JCO.2016.71.3230. Epub 2017 Apr 7.

8.

18F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients.

O'Doherty J, Jauregui-Osoro M, Brothwood T, Szyszko T, Marsden PK, O'Doherty MJ, Cook GJR, Blower PJ, Lewington V.

J Nucl Med. 2017 Oct;58(10):1666-1671. doi: 10.2967/jnumed.117.192252. Epub 2017 Apr 6.

9.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A.

JAMA Oncol. 2017 Jan 1;3(1):58-66. doi: 10.1001/jamaoncol.2016.3049.

PMID:
27584578
10.

The role of new PET tracers for lung cancer.

Szyszko TA, Yip C, Szlosarek P, Goh V, Cook GJ.

Lung Cancer. 2016 Apr;94:7-14. doi: 10.1016/j.lungcan.2016.01.010. Epub 2016 Jan 21. Review.

PMID:
26973200
11.

Role of ¹⁸F-FDG PET imaging in paediatric primary dystonia and dystonia arising from neurodegeneration with brain iron accumulation.

Szyszko TA, Dunn JT, O'Doherty MJ, Reed L, Lin JP.

Nucl Med Commun. 2015 May;36(5):469-76. doi: 10.1097/MNM.0000000000000273.

PMID:
25646707
12.

Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors.

Papastefanou VP, Islam S, Szyszko T, Grantham M, Sagoo MS, Cohen VM.

Br J Ophthalmol. 2014 Dec;98(12):1659-65. doi: 10.1136/bjophthalmol-2014-305304. Epub 2014 Aug 1.

13.

The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma.

El-Najjar I, Montoto S, McDowell A, Matthews J, Gribben J, Szyszko TA.

Nucl Med Commun. 2014 Mar;35(3):311-5. doi: 10.1097/MNM.0000000000000059.

PMID:
24323311
14.

Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.

Szlosarek PW, Luong P, Phillips MM, Baccarini M, Stephen E, Szyszko T, Sheaff MT, Avril N.

J Clin Oncol. 2013 Mar 1;31(7):e111-3. doi: 10.1200/JCO.2012.42.1784. Epub 2013 Jan 14. No abstract available.

PMID:
23319692
15.

Differential uptake of 18F-FDG in patients with synchronous lung cancers.

Navalkissoor S, Szyszko T, Rankin S, Gnanasegaran G.

Ann Nucl Med. 2011 May;25(4):299-302. doi: 10.1007/s12149-010-0457-8. Epub 2011 Jan 14.

PMID:
21234727
16.

Diffuse FDG renal uptake in lymphoma.

Navalkissoor S, Szyszko T, Gnanasegaran G, Nunan T.

Clin Nucl Med. 2010 Oct;35(10):813-5. doi: 10.1097/RLU.0b013e3181ef0add.

PMID:
20838296
17.

Generalized melanosis and melanuria in a patient with metastatic melanoma.

Perez A, Turajlic S, Szyszko T, O'Doherty M, Calonje E, Harries M, Acland K.

Clin Exp Dermatol. 2010 Apr;35(3):e37-9. doi: 10.1111/j.1365-2230.2009.03545.x. No abstract available.

PMID:
20500171
18.

FDG-PET/CT as a molecular biomarker in ovarian cancer.

Nowosinska E, Avril S, Murray I, Szyszko T, Avril N.

Cancer Biomark. 2010-2011;8(4-5):167-75. doi: 10.3233/CBM-2011-0219. Review.

PMID:
22045351
19.

Interesting image. Situs inversus totalis in newly diagnosed lymphoma: additional value of hybrid imaging.

Trautner M, Szyszko T, Gnanasegaran G, Nunan T.

Clin Nucl Med. 2010 Jan;35(1):26-8. doi: 10.1097/RLU.0b013e3181c36138. No abstract available.

PMID:
20026969
20.

Respiratory papillomatosis of lung and F-18 FDG PET-CT.

Szyszko T, Gnanasegaran G, Barwick T, Breen R, Cane P, Rankin S.

Clin Nucl Med. 2009 Aug;34(8):521-2. doi: 10.1097/RLU.0b013e3181abb71c. No abstract available.

PMID:
19617733
21.

Therapy options for treatment of hepatic malignancy.

Szyszko T, Brooks A, Tait P, Rubello D, AL-Nahhas A.

Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1824-6. doi: 10.1007/s00259-008-0798-x. No abstract available.

PMID:
18536915
22.

Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours.

Khodjibekova M, Szyszko T, Khan S, Nijran K, Tait P, Al-Nahhas A.

Rev Recent Clin Trials. 2007 Sep;2(3):212-6. Review.

PMID:
18474007
23.

PET imaging in endocrine tumours.

Khan S, Lloyd C, Szyszko T, Win Z, Rubello D, Al-Nahhas A.

Minerva Endocrinol. 2008 Jun;33(2):41-52. Review.

24.

Treatment of primary and secondary liver tumours with selective internal radiation therapy.

Khodjibekova M, Szyszko T, Singh A, Tait P, Rubello D, Al-Nahhas A.

J Exp Clin Cancer Res. 2007 Dec;26(4):561-70.

PMID:
18365553
25.

Evaluation of hepatic angiography procedures and bremsstrahlung imaging in selective internal radiation therapy: a two-year single-center experience.

Sebastian AJ, Szyszko T, Al-Nahhas A, Nijran K, Tait NP.

Cardiovasc Intervent Radiol. 2008 May-Jun;31(3):643-9. doi: 10.1007/s00270-008-9298-4. Epub 2008 Feb 14.

PMID:
18273668
26.

Gallium-68 PET: a new frontier in receptor cancer imaging.

Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello D.

Anticancer Res. 2007 Nov-Dec;27(6B):4087-94. Review.

27.

What can gallium-68 PET add to receptor and molecular imaging?

Al-Nahhas A, Win Z, Szyszko T, Singh A, Khan S, Rubello D.

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1897-901. No abstract available.

PMID:
17713764
28.

Acrometastasis to the foot: an unusual presentation of transitional cell carcinoma of the bladder.

Khan S, Win Z, Lloyd CR, Neriman D, Szyszko TA, Svensson WE, Al-Nahhas A.

Nucl Med Rev Cent East Eur. 2007;10(1):26-8.

PMID:
17694499
29.

PET Imaging of Pheochromocytoma.

Khan S, Win Z, Szyszko T, Lloyd C, Dunn J, Alavi A, Al-Nahhas A.

PET Clin. 2007 Jul;2(3):341-9. doi: 10.1016/j.cpet.2008.04.003. Epub 2008 Sep 19. Review.

PMID:
27158015
30.

Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours.

Jiao LR, Szyszko T, Al-Nahhas A, Tait P, Canelo R, Stamp G, Wasan H, Lowdell C, Philips R, Thillainayagam A, Bansi D, Rubello D, Limongelli P, Woo K, Habib NA.

Eur J Surg Oncol. 2007 Jun;33(5):597-602. Epub 2007 Apr 11.

PMID:
17433608
31.

Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres.

Szyszko T, Al-Nahhas A, Tait P, Rubello D, Canelo R, Habib N, Jiao L, Wasan H, Bansi D, Thillainayagam A, Nijran K, Stamp G, O'Rourke E.

Nucl Med Commun. 2007 Jan;28(1):21-4.

PMID:
17159545
32.

Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.

Szyszko T, Al-Nahhas A, Canelo R, Habib N, Jiao L, Wasan H, Pagou M, Tait P.

Nucl Med Commun. 2007 Jan;28(1):15-20.

PMID:
17159544
33.
34.

Endoanal magnetic resonance imaging of fistula-in-ano: a comparison of STIR with gadolinium-enhanced techniques.

Szyszko TA, Bush J, Gishen P, Sellu D, Desouza NM.

Acta Radiol. 2005 Feb;46(1):3-8.

PMID:
15841733
35.

Imaging of periosteal reactions associated with focal lesions of bone.

Wenaden AE, Szyszko TA, Saifuddin A.

Clin Radiol. 2005 Apr;60(4):439-56. Review.

PMID:
15767101

Supplemental Content

Loading ...
Support Center